Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder
Authors:
- Hiroshi KurodaHKHiroshi Kuroda
- Kazuo FujiharaKFKazuo Fujihara
- Kimihiko KanekoKKKimihiko Kaneko
- Yoshiki TakaiYTYoshiki Takai
- Yuki MatsumotoYMYuki Matsumoto
- Mizuki OtomoMOMizuki Otomo
- Naoya YamazakiNYNaoya Yamazaki
- Shu UmezawaSUShu Umezawa
- Naoki YamamotoNYNaoki Yamamoto
- Naohiro SakamotoNSNaohiro Sakamoto
- Chihiro NamatameCNChihiro Namatame
- Hirohiko OnoHOHirohiko Ono
Open Access
- 18 January 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 951
Abstract
In this study, blood cell counts and serum C3, C4, and CH50 values at baseline and after more than 6-month drug use were measured to elucidate changes in blood cells and complements during relapse prevention therapies for aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD). A total of 70 patients with AQP4+ NMOSD (87% female, median age 56 years) were enrolled. They were divided into the following treatment groups: glucocorticoids and/or immunosuppressants (GC/IS, n = 22), inebilizumab/rituximab (anti-CD19/20, n = 13), satralizumab (anti-IL-6R, n = 22), and eculizumab/ravulizumab (anti-C5, n = 13). At baseline, the blood counts and complement levels did not differ among the groups. At follow-up, the neutrophil and platelet counts in the anti-IL-6R group decreased from those at baseline (p < 0.0001 and p < 0.001, respectively). Compared with the GC/IS, anti-CD19/20, and anti-C5 groups, the anti-IL-6R group had lower levels of C3 (p < 0.0001, p < 0.01, and p < 0.05, respectively) and C4 (p < 0.0001, p < 0.01, p < 0.001, respectively). Furthermore, the anti-C5 group had significantly lower CH50 levels than the GC/IS, anti-CD19/20, and anti-IL-6R groups (p < 0.0001, p < 0.0001, p < 0.05, respectively). In addition, the anti-IL-6R group had lower CH50 levels than the GC/IS and anti-CD19/20 groups (p < 0.001 and p < 0.05, respectively). The present study demonstrated that anti-IL-6R therapy broadly and mildly suppressed the complement system and decreased the neutrophil and platelet counts. It also showed that anti-C5 therapy strongly suppressed total complement activity but did not affect the C3 and C4 levels or blood counts. These findings may have implications for the mode of action of the drugs and the risk of adverse drug reactions, including infections.Keywords
Funding Information
- JSPS KAKENHI (19K07953)
- JSPS KAKENHI (17H04192)
This publication has 49 references indexed in Scilit:
- Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing SurveillanceNeurology and Therapy, 2025
- Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumabAutoimmunity Reviews, 2025
- Stage-dependent immunity orchestrates AQP4 antibody-guided NMOSD pathology: a role for netting neutrophils with resident memory T cells in situActa Neuropathologica, 2024
- Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum DisorderAnnals of Neurology, 2023
- Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patientsClinical Rheumatology, 2018
- Efficacy and safety of rituximab for systemic lupus erythematosus‐associated immune cytopenias: A multicenter retrospective cohort study of 71 adultsAmerican Journal of Hematology, 2017
- Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersNeurotherapeutics, 2016
- Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacksClinica Chimica Acta, 2013
- Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cellsBiochemical and Biophysical Research Communications, 2010
- Interleukin 6, the third mediator of acute‐phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 β and tumor necrosis factor‐αEuropean Journal of Immunology, 1988